Metformin Zentiva

Metformin, the active ingredient in Metformin Zentiva, is a biguanide presented as an oral tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus and in individuals with impaired glucose tolerance. GNH USA supplies Metformin Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Zentiva is an oral biguanide indicated for disorders of glucose metabolism. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes. - Polycystic ovary syndrome (insulin resistance): improves metabolic parameters associated with insulin resistance.

Metformin may cause a range of adverse reactions, most of which are related to the gastrointestinal tract, while rare events can be serious.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: frequent loose stools. - Abdominal discomfort: cramping or pain. - Metallic taste: transient alteration of taste. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption over long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: life‑threatening accumulation of lactate. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic failure: impaired liver function. - Hypoglycaemia: when combined with other glucose‑lowering agents. - Acute pancreatitis: inflammation of the pancreas. - Anemia: due to reduced red blood cell production.

Metformin should be used with careful clinical monitoring to minimise risks. - Renal function assessment: evaluate creatinine clearance before initiation and periodically thereafter. - Hepatic function monitoring: avoid use in patients with significant liver disease. - Lactic acidosis risk: discontinue before any radiographic contrast procedures. - Elderly patients: start at lower dose and titrate slowly. - Alcohol consumption: limit intake to reduce lactic acidosis risk. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of lactic acidosis. - Cimetidine: may raise metformin plasma concentrations. - Alcohol: potentiates lactic acidosis. - Carbamazepine: reduces metformin effectiveness. - Rifampin: decreases metformin plasma levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Thiazide diuretics: can affect renal clearance. - ACE inhibitors: monitor renal function. - NSAIDs: may impair renal excretion. - Digoxin: watch for altered plasma levels.